STAT6
STAT6 is a cytokine-responsive transcription factor that links receptor signaling to gene regulation in immune cells[1]. Mechanistically, IL-4 and IL-13 activate STAT6, and this axis drives TH2 polarization, IL-4-dependent lymphocyte responses, and IgE class switching[1][2][3]. In disease models, STAT6 regulates pathologic lung inflammation and supports experimental analysis of allergic asthma, airway hyperresponsiveness, and atopic inflammation[4][5][6]. Compared with related STAT isoforms, STAT6 shows a distinct functional focus on IL-4/IL-13 biology, whereas STAT4 primarily controls TH1 differentiation[7]. For experimental applications, STAT6 inhibition with AS1517499 reduced antigen-induced bronchial hypercontractility and blocked STAT6 signaling in mouse atopic dermatitis-asthma models[5][6].
References:
- [1]. Hebenstreit D, et al. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev. 2006 Jun;17(3):173-88. [Content Brief]
- [2]. Takeda K, et al. Essential role of Stat6 in IL-4 signalling. Nature. 1996 Apr 18;380(6575):627-30. [Content Brief]
- [3]. Shimoda K, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 1996 Apr 18;380(6575):630-3. [Content Brief]
- [4]. Walford HH, et al. STAT6 and lung inflammation. JAKSTAT. 2013 Oct 1;2(4):e25301. [Content Brief]
- [5]. Chiba Y, et al. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am J Respir Cell Mol Biol. 2009 Nov;41(5):516-24. [Content Brief]
- [6]. Li X, et al. The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway. Allergy Asthma Clin Immunol. 2022 Feb 17;18(1):12. [Content Brief]
- [7]. Lund RJ, et al. Kinetics and STAT4- or STAT6-mediated regulation of genes involved in lymphocyte polarization to Th1 and Th2 cells. Eur J Immunol. 2003 Apr;33(4):1105-16. [Content Brief]
-
STAT6 Related Products (61)
Related Products (61)
-
Antibodies (1)
-
STAT6-IN-11
0 ImagesCat. No.: HY-185073CAS No.: 3092076-12-2STAT6-IN-11 is a STAT6 inhibitor with an EC50 of 0.006 μM. STAT6-IN-11 can be used for the research of dermatological condition or respiratory conditions.
-
Pabgraminone C
0 ImagesCat. No.: HY-184119CAS No.: 3061276-55-6Synonyms: IM502Pabgraminone C (IM502) is a Fungal metabolite and PI3Kγ inhibitor with an IC50 of 61.7 nM against PI3Kγ. Pabgraminone C shifts the STAT signaling pathway in cells from an immunosuppressive STAT3/STAT6-dominant profile to an immunostimulatory STAT1/STAT2-dominant profile, driving cells toward a pro-inflammatory phenotype. Pabgraminone C reprograms cells from an immunosuppressive state to an immunostimulatory state, reversing their suppressive effect on anti-tumor immunity. Pabgraminone C inhibits established tumor growth and metastasis across multiple cancer types. Pabgraminone C overcomes resistance to PD-1 checkpoint blockade strategies. Pabgraminone C can be used in research related to liver cancer, melanoma, and colorectal cancer.
-
Tofacitinib-13C,d3
0 ImagesCat. No.: HY-40354S2Synonyms: Tasocitinib-13C,d3; CP-690550-13C,d3Tofacitinib-13C,d3 (Tasocitinib-13C,d3; CP-690550-13C,d3) is the deuterated, 13C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.
-
STAT6-IN-7
0 ImagesSTAT6-IN-7 is a STAT6 inhibitor. STAT6-IN-7 exhibits an IC50 of 0.28 μM for inhibiting the binding of human STAT6/pIL-4Rα. STAT6-IN-7 can be used in the research of atopic dermatitis.
-
(trans)-STAT6-IN-13
0 ImagesCat. No.: HY-164216A
-
STAT6-IN-8
0 ImagesSTAT6-IN-8 is a STAT6 inhibitor with an IC50 of 0.45 μmol/L. STAT6-IN-8 exhibits potential anti-inflammatory and anti-allergic effects. STAT6-IN-8 can be used for the research of atopic dermatitis.
-
Phoenixin-20 TFA
0 ImagesCat. No.: HY-P5763ASynonyms: PNX-20 TFAPhoenixin-20 TFA (PNX-20 TFA) is a neuropeptide that activates GPR173. Phoenixin-20 TFA inhibits LPS-induced TLR-4/MyD88/NF-κB signaling, pro-inflammatory cytokines, adhesion molecules, MMPs, and cytotoxicity. Phoenixin-20 TFA increases SIRT1 and inhibits NLRP3/ASC/caspase-1, oxidative stress, and IL-1β/IL-18. Phoenixin-20 TFA alleviates ox-LDL-induced endothelial dysfunction, monocyte adhesion, adhesion molecules, cytokines, NADPH oxidase/NOX-4, and ROS. Phoenixin-20 TFA promotes GPR173/STAT6-mediated anti-inflammatory polarization of microglia and neuroprotection. Phoenixin-20 TFA can be used in research on dental pulp infection, pulmonary arterial hypertension, atherosclerosis, neuroinflammation, anxiety, and neurodegenerative diseases.
-
STAT6-IN-9
0 ImagesSTAT6-IN-9 is a potent STAT6 inhibitor with an EC50 value of 4 nM. STAT6-IN-9 effectively blocks STAT6 activation mediated by the IL-13-IL-13 receptor/IL-4 receptor pathway. STAT6-IN-9 inhibits CCL17 secretion with an IC50 value of 4.6 nM. STAT6-IN-9 can be used to investigate various chronic inflammatory diseases mediated by STAT6, such as allergy, asthma, and chronic obstructive pulmonary disease.
-
AK305
0 ImagesCat. No.: HY-184991CAS No.: 2982853-56-3AK305 is a small-molecule ligand for the SH2 domains of STAT5A, STAT5B and STAT6, with a Ki of 0.4 μM for STAT6 and a Ki of 1.0 μM for both STAT5A and STAT5B. AK305 exhibits only very low or no cell growth inhibitory activity in leukemia cells and does not alter STAT protein levels. AK305 serves as the STAT5 ligand for AK-2292 (HY-148813), a STAT5 PROTAC degrader. AK305 can be used in the research of acute myeloid leukemia.
-
PROTAC STAT6 degrader-10
0 ImagesCat. No.: HY-183847CAS No.: 3077464-23-1PROTAC STAT6 degrader-10 is a bifunctional STAT6 degrader with a DC50 value of >1 μM. PROTAC STAT6 degrader-10 recruits STAT6 protein to E3 ubiquitin ligase for ubiquitination and subsequent degradation. PROTAC STAT6 degrader-10 can be used for the research of inflammatory disorders, allergies, asthma, eczema.
-
STAT6-IN-12
0 ImagesCat. No.: HY-162405CAS No.: 2949393-27-3STAT6-IN-12 is a potent STAT6 inhibitor with an IC50 of 50 nM. STAT6-IN-12 also inhibits Smad2/3 with an IC50 of 68 nM. STAT6-IN-12 inhibits TGFβ-dependent Smad2/3 signaling pathway, IL-4-dependent STAT6 signaling pathway, and cellular inflammatory responses. STAT6-IN-12 can be used for the research of inflammation.
-
Tofacitinib-13C3,15N
0 ImagesCat. No.: HY-40354S1Purity: 99.57%Synonyms: Tasocitinib-13C3,15N; CP-690550-13C3,15NTofacitinib-13C3,15N (Tasocitinib-13C3,15N; CP-690550-13C3,15N) is the 15N, 13C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.
-
Tofacitinib hydrochloride
0 ImagesCat. No.: HY-40354HCAS No.: 1803005-18-6Synonyms: Tasocitinib hydrochloride; CP-690550 hydrochlorideTofacitinib hydrochloride (Tasocitinib hydrochloride) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib hydrochloride blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib hydrochloride can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.
-
Tofacitinib-13C
0 ImagesCat. No.: HY-40354S3Synonyms: Tasocitinib-13C; CP-690550-13CTofacitinib-13C (Tasocitinib-13C; CP-690550-13C) is the 13C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.
-
Tofacitinib-d3
0 ImagesCat. No.: HY-40354S5Synonyms: Tasocitinib-d3; CP-690550-d3Tofacitinib-d3 (Tasocitinib-d3; CP-690550-d3) is the deuterated-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.
